General
Preferred name
Ipragliflozin
Synonyms
ASP1941 ()
IPRAGLIFLOZIN L-PROLINE ()
Ipragliflozin (ASP1941) ()
Ipragliflozine ()
ASP-1941 ()
Ipragliflozina ()
Ipragliflozin-13C6 ()
P&D ID
PD073709
CAS
761423-87-4
Tags
available
drug
Approved by
PMDA
First approval
2014
Drug indication
Liver disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ipragliflozin is a selective and orally available sodium/glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor (a 'gliflozin' family drug ) used to treat type 2 diabetes. In practice ipragliflozin is complexed with L-proline in a 1:1 ratio. (GtoPdb)
Compound Sets
15
AdooQ Bioactive Compound Library
A13556
Cayman Chemical Bioactives
22287
28705
ChEMBL Approved Drugs
CHEMBL2018096
ChEMBL Drugs
CHEMBL2018096
Drug Repurposing Hub
DrugBank
DB11698
DrugCentral
4890
DrugCentral Approved Drugs
4890
DrugMAP
DMGQ1TV
EU-OPENSCREEN Bioactive Compound Library
EOS100989
Guide to Pharmacology
9394
MedChem Express Bioactive Compound Library
HY-14894
ReFrame library
Selleckchem Bioactive Compound Library
ipragliflozin-asp-1941
TargetMol Bioactive Compound Library
T2385
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
404.11
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
3
cLogP
2.15
TPSA
90.15
Fraction CSP3
0.33
Chiral centers
5.0
Largest ring
6.0
QED
0.54
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Membrane Transporter/Ion Channel
Target
SGLT2
SLC5A2
SGLT
Indication
diabetes mellitus
MOA
sodium/glucose cotransporter inhibitor
Source data